Targeting Natural Killer Cells: from Basic Biology to Clinical Application in Hematologic Malignancies

Overview

Journal Exp Hematol Oncol

Publisher Biomed Central

Specialty Hematology

Date 2024 Feb 23

PMID 38396050

Authors

Juanjuan Shang

Shunfeng Hu

Xin Wang

Affiliations

Soon will be listed here.

Abstract

Natural killer (NK) cell belongs to innate lymphoid cell family that contributes to host immunosurveillance and defense without pre-immunization. Emerging studies have sought to understand the underlying mechanism behind NK cell dysfunction in tumor environments, and provide numerous novel therapeutic targets for tumor treatment. Strategies to enhance functional activities of NK cell have exhibited promising efficacy and favorable tolerance in clinical treatment of tumor patients, such as immune checkpoint blockade (ICB), chimeric antigen receptor NK (CAR-NK) cell, and bi/trispecific killer cell engager (BiKE/TriKE). Immunotherapy targeting NK cell provides remarkable advantages compared to T cell therapy, including a decreased rate of graft versus-host disease (GvHD) and neurotoxicity. Nevertheless, advanced details on how to support the maintenance and function of NK cell to obtain better response rate and longer duration still remain to be elucidated. This review systematically summarizes the profound role of NK cells in tumor development, highlights up-to-date advances and current challenges of therapy targeting NK cell in the clinical treatment of hematologic malignancies.

Citing Articles

Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed/refractory AML: preclinical evaluation and phase I trial.

Huang R, Wang X, Yan H, Tan X, Ma Y, Wang M Exp Hematol Oncol. 2025; 14(1):1.

PMID: 39748428 PMC: 11694373. DOI: 10.1186/s40164-024-00592-6.

Advancements in immunotherapy for colorectal cancer treatment: a comprehensive review of strategies, challenges, and future prospective.

Kaviyarasan V, Das A, Deka D, Saha B, Banerjee A, Sharma N Int J Colorectal Dis. 2024; 40(1):1.

PMID: 39731596 PMC: 11682016. DOI: 10.1007/s00384-024-04790-w.

Engineering a controllable and reversible switch for CAR-based cellular immunotherapies via a genetic code expansion system.

Liu Y, An L, Wang X, Dai Y, Zhang C, Wen Q J Hematol Oncol. 2024; 17(1):122.

PMID: 39696585 PMC: 11657976. DOI: 10.1186/s13045-024-01648-0.

Role of T Lymphocytes in Glioma Immune Microenvironment: Two Sides of a Coin.

Noor L, Upadhyay A, Joshi V Biology (Basel). 2024; 13(10).

PMID: 39452154 PMC: 11505600. DOI: 10.3390/biology13100846.

The next frontier in immunotherapy: potential and challenges of CAR-macrophages.

Li J, Chen P, Ma W Exp Hematol Oncol. 2024; 13(1):76.

PMID: 39103972 PMC: 11302330. DOI: 10.1186/s40164-024-00549-9.

References

Arvindam U, van Hauten P, Schirm D, Schaap N, Hobo W, Blazar B . A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells. Leukemia. 2020; 35(6):1586-1596. PMC: 8189652. DOI: 10.1038/s41375-020-01065-5. View

Nguyen R, Wu H, Pounds S, Inaba H, Ribeiro R, Cullins D . A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia. J Immunother Cancer. 2019; 7(1):81. PMC: 6425674. DOI: 10.1186/s40425-019-0564-6. View

Gomez Garcia L, Escudero A, Mestre C, Fuster Soler J, Martinez A, Vagace Valero J . Phase 2 Clinical Trial of Infusing Haploidentical K562-mb15-41BBL-Activated and Expanded Natural Killer Cells as Consolidation Therapy for Pediatric Acute Myeloblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2021; 21(5):328-337.e1. DOI: 10.1016/j.clml.2021.01.013. View

Oei V, Siernicka M, Graczyk-Jarzynka A, Hoel H, Yang W, Palacios D . Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors. Cancer Immunol Res. 2018; 6(4):467-480. DOI: 10.1158/2326-6066.CIR-17-0207. View

Guan J, Wang R, Hasan S, Tao L, Wazir M, Jain A . Prognostic Significance of the Dynamic Change of Programmed Death-ligand 1 Expression in Patients with Multiple Myeloma. Cureus. 2019; 11(4):e4401. PMC: 6559697. DOI: 10.7759/cureus.4401. View

Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N . The cancer metabolic reprogramming and immune response. Mol Cancer. 2021; 20(1):28. PMC: 7863491. DOI: 10.1186/s12943-021-01316-8. View

Chan W, Kang S, Youssef Y, Glankler E, Barrett E, Carter A . A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma. Cancer Immunol Res. 2018; 6(7):776-787. PMC: 6030494. DOI: 10.1158/2326-6066.CIR-17-0649. View

Street S, Cretney E, Smyth M . Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood. 2001; 97(1):192-7. DOI: 10.1182/blood.v97.1.192. View

DiLillo D, Weinberg J, Yoshizaki A, Horikawa M, Bryant J, Iwata Y . Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function. Leukemia. 2012; 27(1):170-82. PMC: 3742013. DOI: 10.1038/leu.2012.165. View

10.

Yan Y, Zheng L, Du Q, Yazdani H, Dong K, Guo Y . Interferon regulatory factor 1(IRF-1) activates anti-tumor immunity via CXCL10/CXCR3 axis in hepatocellular carcinoma (HCC). Cancer Lett. 2021; 506:95-106. PMC: 8009854. DOI: 10.1016/j.canlet.2021.03.002. View

11.

Qu C, Zhang H, Cao H, Tang L, Mo H, Liu F . Tumor buster - where will the CAR-T cell therapy 'missile' go?. Mol Cancer. 2022; 21(1):201. PMC: 9580202. DOI: 10.1186/s12943-022-01669-8. View

12.

Topalian S, Drake C, Pardoll D . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27(4):450-61. PMC: 4400238. DOI: 10.1016/j.ccell.2015.03.001. View

13.

Hu F, Wang Y, Wang W, Gale R, Wu B, Liang Y . Improving prediction accuracy in acute myeloid leukaemia: micro-environment, immune and metabolic models. Leukemia. 2021; 35(11):3073-3077. PMC: 8550966. DOI: 10.1038/s41375-021-01377-0. View

14.

Liu X, Song J, Zhang H, Liu X, Zuo F, Zhao Y . Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance. Cancer Cell. 2023; 41(2):272-287.e9. DOI: 10.1016/j.ccell.2023.01.001. View

15.

Wang X, Yang X, Yuan X, Wang W, Wang Y . Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential. Exp Hematol Oncol. 2022; 11(1):85. PMC: 9628181. DOI: 10.1186/s40164-022-00341-7. View

16.

Badrinath S, Dellacherie M, Li A, Zheng S, Zhang X, Sobral M . A vaccine targeting resistant tumours by dual T cell plus NK cell attack. Nature. 2022; 606(7916):992-998. PMC: 10253041. DOI: 10.1038/s41586-022-04772-4. View

17.

Rosenberg S, Mule J, Spiess P, Reichert C, Schwarz S . Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med. 1985; 161(5):1169-88. PMC: 2187617. DOI: 10.1084/jem.161.5.1169. View

18.

Ghiringhelli F, Menard C, Terme M, Flament C, Taieb J, Chaput N . CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med. 2005; 202(8):1075-85. PMC: 2213209. DOI: 10.1084/jem.20051511. View

19.

Baek A, Yu Y, He S, Wardell S, Chang C, Kwon S . The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells. Nat Commun. 2017; 8(1):864. PMC: 5636879. DOI: 10.1038/s41467-017-00910-z. View

20.

Sauer M, Schuldner M, Hoffmann N, Cetintas A, Reiners K, Shatnyeva O . CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells. Oncogene. 2016; 36(7):933-941. PMC: 5318661. DOI: 10.1038/onc.2016.259. View